CD22 and autoimmune disease

International Reviews of Immunology

Volumn 31, Issue 5, 2012, Pages 363-378

  Dörner, Thomas ^a   Shock, Anthony ^b   Smith, Kenneth G C ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UCB PHARMA   (Belgium)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Autoimmunity; B cells; BCR; Co receptor; Intracellular signaling; Siglec

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD22 ANTIGEN; EPRATUZUMAB; RITUXIMAB;

ANCA ASSOCIATED VASCULITIS; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL ADHESION; CELL MATURATION; CELL MIGRATION; DRUG MECHANISM; HUMAN; INTERNALIZATION; INTRACELLULAR SIGNALING; LIGAND BINDING; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOIMMUNITY; B-LYMPHOCYTES; GENE EXPRESSION REGULATION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCR; SIALIC ACID BINDING IG-LIKE LECTIN 2; SIGNAL TRANSDUCTION;

EID: 84867760845     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2012.709890     Document Type: Article

References (121)

1. Fiorina P, SayeghMH.Bcell-targeted therapies in autoimmunity: Rationale and progress. F1000Biol Rep. 2009;1:39-42.
2. Crampton SP, Voynova E, Bolland S. Innate pathways to B-cell activation and tolerance. Ann N Y Acad Sci. 2010;1183:58-68.
3. Levesque MC. TranslationalMini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol. 2009;157:198-208.
4. Poe JC,HasegawaM, Tedder TF. CD19, CD21, andCD22:multifaceted response regulators of B lymphocyte signal transduction. Int Rev Immunol. 2001;20:739-762.
5. Pritchard NR, Smith KGC. B cell inhibitory receptors and autoimmunity. Immunology. 2003;108:263-273.
6. Cyster JG,GoodnowCC. Tuning antigen receptor signaling by CD22: Integrating cues fromantigens and the microenvironment. Immunity. 1997;6:509-517.
7. Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol. 1997;15:481-504.
8. Sato S, Miller AS, Inaoki M, et al. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: Altered signaling in CD22-deficient mice. Immunity. 1996;5:551-562.
9. Nitschke L.The role of CD22 and other inhibitory co-receptors in B-cell activation. Curr Opin Immunol. 2005;17:290-297.
10. Grimaldi CM,Hicks R,Diamond B. B cell selection and susceptibility to autoimmunity. J Immunol. 2005;174:1775-1781.
11. Walker JA, Smith KG. CD22: An inhibitory enigma. Immunology. 2008;123:314-325.
12. PezzuttoA,DorkenB,Moldenhauer G, Clark EA. Amplification of humanBcell activation by amonoclonal antibody to the B cell-specific antigen CD22, Bp 130/140. J Immunol. 1987;138:98-103.
13. Pezzutto A, Rabinovitch PS, Dorken B, Moldenhauer G, Clark EA. Role of the CD22 human B cell antigen in B cell triggering by anti-immunoglobulin. J Immunol. 1988;140:1791-1795.
14. Stamenkovic I, Seed B.TheB-cell antigen CD22mediatesmonocyte and erythrocyte adhesion. Nature. 1990;345:74-77.
15. Wilson GL, Fox CH, Fauci AS, Kehrl JH. cDNA cloning of the B cellmembrane protein CD22: Amediator of B-B cell interactions. J ExpMed. 1991;173:137-146.
16. Tedder TF, Poe JC,Haas KM. CD22: Amultifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol. 2005;88:1-50.
17. Daridon C,BlassfeldD,ReiterK, et al. Epratuzumab targeting of CD22 affects adhesion molecule expression andmigration of B-cells in systemic lupus erythematosus. Arthritis ResTher. 2010;12:R204.
18. Nitschke L,Carsetti R, Ocker B,KohlerG, Lamers MC. CD22 is a negative regulator of B-cell receptor signalling. Curr Biol. 1997;7:133-143.
19. SmithKGC,HewitsonTD,NossalGJ,TarlintonDM.Thephenotype andfate of the antibody-forming cells of the splenic foci. Eur J Immunol. 1996;26:444-448.
20. Wen T,Mingler MK, Blanchard C, et al.The pan-B cellmarker CD22 is expressed on gastrointestinal eosinophils and negatively regulates tissue eosinophilia. J Immunol. 2012;188:1075-1082.
21. Sgroi D, Varki A, Braesch-Andersen S, Stamenkovic I. CD22, a B cell-specific immunoglobulin superfamilymember, is a sialic acid-binding lectin. J Biol Chem. 1993;268:7011-7018.
22. von Gunten S, Bochner BS. Basic and clinical immunology of Siglecs. Ann N Y Acad Sci. 2008;1143:61-82.
23. Powell LD, Jain RK,Matta KL, Sabesan S, Varki A. Characterization of sialyloligosaccharide binding by recombinant soluble and native cell-associated CD22: Evidence for a minimal structural recognition motif and the potential importance ofmultisite binding. J Biol Chem. 1995;270:7523-7532.
24. Hanasaki K, Powell LD, Varki A. Binding of human plasma sialoglycoproteins by the B cellspecific lectin CD22: Selective recognition of immunoglobulin M and haptoglobin. J Biol Chem. 1995;270:7543-7550.
25. Powell LD, Sgroi D, Sjoberg ER, Stamenkovic I, Varki A. Natural ligands of the B cell adhesion molecule CD22 beta carry N-linked oligosaccharides with alpha-2,6-linked sialic acids that are required for recognition. J Biol Chem. 1993;268:7019-7027.
26. Jellusova J, Nitschke L. Regulation of b cell functions by the sialic acid-binding receptors Siglec-G and CD22. Front Immunol. 2011;2:96.
27. Engel P, Wagner N, Miller AS, Tedder TF. Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand. J ExpMed. 1995;181:1581-1586.
28. Law CL, Aruffo A, Chandran KA, Doty RT, Clark EA. Ig domains 1 and 2 of murine CD22 constitute the ligand-binding domain and bind multiple sialylated ligands expressed on B and T cells. J Immunol. 1995;155:3368-3376.
29. Nath D, van derMerwe PA, Kelm S, Bradfield P, Crocker PR.Theamino-terminal immunoglobulinlike domain of sialoadhesin contains the sialic acid binding site: Comparison with CD22. J Biol Chem. 1995;270:26184-26191.
30. van derMerwe PA, Crocker PR, Vinson M, et al. Localization of the putative sialic acid-binding site on theimmunoglobulin superfamily cell-surfacemolecule CD22. J Biol Chem. 1996;271:9273-9280.
31. Flaswinkel H, Reth M.Dual role of the tyrosine activation motif of the Ig-alpha protein during signal transduction via the B cell antigen receptor. EMBO J. 1994;13:83-89.
32. Smith KGC, Tarlinton DM, Doody GM, Hibbs ML, Fearon DT. Inhibition of the B cell by CD22: A requirement for Lyn. J ExpMed. 1998;187:807-811.
33. Cornall RJ, Cyster JG, Hibbs ML, et al. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity. 1998;8:497-508.
34. Xu Y, Harder KW, Huntington ND, Hibbs ML, Tarlinton DM. Lyn tyrosine kinase: Accentuating the positive and the negative. Immunity. 2005;22:9-18.
35. Fujimoto M, Kuwano Y, Watanabe R, et al. B cell antigen receptor and CD40 differentially regulate CD22 tyrosine phosphorylation. J Immunol. 2006;176:873-879.
36. Leprince C, Draves KE,GeahlenRL, Ledbetter JA, Clark EA. CD22associateswith the humansurface IgM-B-cell antigen receptor complex. Proc Natl Acad Sci U S A. 1993;90:3236-3240.
37. Doody GM, Justement LB, Delibrias CC, et al. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science. 1995;269:242-244.
38. Sato S, Jansen PJ, Tedder TF. CD19 and CD22 expression reciprocally regulates tyrosine phosphorylation of Vav protein during B lymphocyte signaling. Proc Natl Acad Sci U S A. 1997;94: 13158-13162.
39. Fujimoto M, Bradney AP, Poe JC, Steeber DA, Tedder TF. Modulation of B lymphocyte antigen receptor signal transduction by a CD19/CD22 regulatory loop. Immunity. 1999;11:191-200.
40. Gerlach J, Ghosh S, Jumaa H, et al. B cell defects in SLP65/BLNK-deficient mice can be partially corrected by the absence of CD22, an inhibitory coreceptor for BCR signaling. Eur J Immunol. 2003;33:3418-3426.
41. Jellusova J, Duber S, Guckel E, et al. Siglec-G regulates B1 cell survival and selection. J Immunol. 2010;185:3277-3284.
42. Bhattacharyya S, Deb J, Patra AK, et al. NFATc1 affectsmouse splenic B cell function by controlling the calcineurin-NFAT signaling network. J ExpMed. 2011;208:823-839.
43. Chen J,McLean PA,Neel BG, et al. CD22 attenuates calcium signaling by potentiating plasmamembrane calcium-ATPase activity. Nat Immunol. 2004;5:651-657.
44. Law CL, Sidorenko SP, Chandran KA, et al. CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation. J ExpMed. 1996;183:547-560.
45. Tuscano JM, Engel P, Tedder TF, Agarwal A, Kehrl JH. Involvement of p72syk kinase, p53/56lyn kinase and phosphatidyl inositol-3 kinase in signal transduction via the human B lymphocyte antigen CD22. Eur J Immunol. 1996;26:1246-1252.
46. Wienands J, Freuler F, Baumann G. Tyrosine-phosphorylated forms of Ig beta, CD22, TCR zeta and HOSS aremajor ligands for tandem SH2 domains of Syk. Int Immunol. 1995;7:1701-1708.
47. Brauweiler AM, Tamir I, Cambier JC. Bilevel control of B-cell activation by the inositol 5-phosphatase SHIP. Immunol Rev. 2000;176:69-74.
48. Stork B, Engelke M, Frey J, et al.Grb2 and the non-T cell activation linkerNTAL constitute a Ca(2+)-regulating signal circuit in B lymphocytes. Immunity. 2004;21:681-691.
49. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Hyperresponsive B cells in CD22-deficient mice. Science. 1996;274:798-801.
50. Otipoby KL, Andersson KB, Draves KE, et al. CD22 regulates thymus-independent responses and the lifespan of B cells. Nature. 1996;384:634-637.
51. Poe JC,Haas KM,Uchida J, et al. Severely impaired B lymphocyte proliferation, survival, and induction of the c-Myc:Cullin 1 ubiquitin ligase pathway resulting fromCD22 deficiency on the C57BL/6 genetic background. J Immunol. 2004;172:2100-2110.
52. Samardzic T,Marinkovic D, Danzer CP, et al. Reduction ofmarginal zone B cells in CD22-deficient mice. Eur J Immunol. 2002;32:561-567.
53. Pillai S. Two lymphoid roads diverge-but does antigen bade B cells to take the road less traveled? Immunity. 2005;23:242-244.
54. Wen L, Brill-Dashoff J, Shinton SA, et al. Evidence of marginal-zone B cell-positive selection in spleen. Immunity. 2005;23:297-308.
55. Cariappa A, Tang M, Parng C, et al. The follicular versusmarginal zone B lymphocyte cell fate decision is regulated by Aiolos, Btk, and CD21. Immunity. 2001;14:603-615.
56. Collins BE, Smith BA, Bengtson P, Paulson JC. Ablation of CD22 in ligand-deficientmice restores B cell receptor signaling. Nat Immunol. 2006;7:199-206.
57. Ghosh S, Bandulet C, Nitschke L. Regulation of B cell development and B cell signalling by CD22 and its ligands alpha2,6-linked sialic acids. Int Immunol. 2006;18:603-611.
58. Hennet T, Chui D, Paulson JC, Marth JD. Immune regulation by the ST6Gal sialyltransferase. Proc Natl Acad Sci U S A. 1998;95:4504-4509.
59. JinL,McLean PA,Neel BG,WortisHH.Sialic acid bindingdomains ofCD22are required for negative regulation of B cell receptor signaling. J ExpMed. 2002;195:1199-1205.
60. Grewal PK, Boton M, Ramirez K, et al. ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling. Mol Cell Biol. 2006;26:4970-4981.
61. Onodera T, Poe JC, Tedder TF, Tsubata T. CD22 regulates time course of both B cell division and antibody response. J Immunol. 2008;180:907-913.
62. Poe JC, Fujimoto Y, Hasegawa M, et al. CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nat Immunol. 2004;5:1078-1087.
63. Goodnow CC, Crosbie J, Adelstein S, et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature. 1988;334:676-682.
64. Kawasaki N, Rademacher C, Paulson JC. CD22 Regulates Adaptive and Innate Immune Responses of B Cells. J Innate Immun. 2011;3:411-419.
65. Kelm S, Gerlach J, Brossmer R, Danzer CP, Nitschke L. The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound. J ExpMed. 2002;195:1207-1213.
66. Razi N, Varki A.Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes. Proc Natl Acad Sci U S A. 1998;95:7469-7474.
67. Razi N, Varki A. Cryptic sialic acid binding lectins on human blood leukocytes can be unmasked by sialidase treatment or cellular activation. Glycobiology. 1999;9:1225-1234.
68. Danzer CP, Collins BE, Blixt O, Paulson JC, Nitschke L. Transitional and marginal zone B cells have a high proportion of unmasked CD22: Implications for BCR signaling. Int Immunol. 2003;15:1137-1147.
69. Peaker CJ, Neuberger MS. Association of CD22 with the B cell antigen receptor. Eur J Immunol. 1993;23:1358-1363.
70. Zhang M, Varki A. Cell surface sialic acids do not affect primary CD22 interactions with CD45 and surface IgM nor the rate of constitutive CD22 endocytosis. Glycobiology. 2004;14:939-949.
71. Han S, Collins BE, Bengtson P, Paulson JC.Homomultimeric complexes of CD22 in B cells revealed by protein-glycan cross-linking. Nat Chem Biol. 2005;1:93-97.
72. Nitschke L, Floyd H, Ferguson DJ, Crocker PR. Identification of CD22 ligands on bone marrow sinusoidal endothelium implicated in CD22-dependent homing of recirculating B cells. J Exp Med. 1999;189:1513-1518.
73. Lanoue A, Batista FD, Stewart M, Neuberger MS. Interaction of CD22 with alpha2,6-linked sialoglycoconjugates: Innate recognition of self to dampen B cell autoreactivity? Eur J Immunol. 2002;32:348-355.
74. Aruffo A, Kanner SB, Sgroi D, Ledbetter JA, Stamenkovic I. CD22-mediated stimulation of T cells regulates T-cell receptor/CD3-induced signaling. Proc Natl Acad Sci U S A. 1992;89:10242-10246.
75. Sgroi D, Koretzky GA, Stamenkovic I. Regulation of CD45 engagement by the B-cell receptor CD22. Proc Natl Acad Sci U S A. 1995;92:4026-4030.
76. Tuscano J, Engel P, Tedder TF, Kehrl JH. Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22/CD22L interactions impairs T-cell proliferation. Blood. 1996;87:4723-4730.
77. Floyd H, Nitschke L, Crocker PR. A novel subset of murine B cells that expresses unmasked forms of CD22 is enriched in the bone marrow: Implications for B-cell homing to the bone marrow. Immunology. 2000;101:342-347.
78. Collins BE, Blixt O, Han S, et al. High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells. J Immunol. 2006;177:2994-3003.
79. Collins BE, Blixt O,DeSienoAR, et al.Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact. Proc Natl Acad Sci U S A. 2004;101:6104-6109.
80. DanchenkoN, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: A comparison of worldwide disease burden. Lupus. 2006;15:308-318.
81. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl JMed. 2008;358:929-939.
82. Martin F, Chan AC. Pathogenic roles of B cells in human autoimmunity: Insights from the clinic. Immunity. 2004;20:517-527.
83. MokMY. The immunological basis of B-cell therapy in systemic lupus erythematosus. Int J Rheum Dis. 2010;13:3-11.
84. Harley IT, Kaufman KM, Langefeld CD, Harley JB, Kelly JA. Genetic susceptibility to SLE: New insights from finemapping and genome-wide association studies. Nat Rev Genet. 2009;10:285-290
85. LeandroMJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46:2673-2677.
86. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580-2589.
87. Dorner T, Kinnman N, Tak PP. Targeting B cells in immune-mediated inflammatory disease: A comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther. 2010;125:464-475.
88. Ahmed S, Anolik JH. B-cell biology and related therapies in systemic lupus erythematosus. Rheum Dis Clin North Am. 2010;36:109-130, viii-ix.
89. Arbuckle MR,McClain MT, Rubertone MV, et al.Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl JMed. 2003;349:1526-1533.
90. Bolland S, Ravetch JV. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficientmice results from strain-specific epistasis. Immunity. 2000;13:277-285.
91. Strasser A, Whittingham S, Vaux DL, et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci U S A. 1991;88:8661-8665.
92. Gross JA, Johnston J,Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404:995-999.
93. StohlW,Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthritis Rheum. 2003;48:3475-3486.
94. Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004;20:785-798.
95. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721-731.
96. O'Keefe TL,WilliamsGT, Batista FD,Neuberger MS.Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med. 1999;189:1307-1313.
97. Nitschke L, Lajaunias F, Moll T, et al. Expression of aberrant forms of CD22 on B lymphocytes in Cd22a lupus-pronemice affects ligand binding. Int Immunol. 2006;18:59-68.
98. Kikuchi S, Fossati-Jimack L,Moll T, et al. Differential role of threemajorNew Zealand Black-derived loci linked with Yaa-inducedmurine lupus nephritis. J Immunol. 2005;174:1111-1117.
99. Kikuchi S, Amano H, Amano E, et al. Identification of 2major loci linked to autoimmune hemolytic anemia in NZB mice. Blood. 2005;106:1323-1329.
100. Lajaunias F, Ibnou-Zekri N, Fossati JL, et al. Polymorphisms in the Cd22 gene of inbred mouse strains. Immunogenetics. 1999;49:991-995.
101. Hibbs ML, Tarlinton DM, Armes J, et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell. 1995;83:301-311.
102. Silver K, Bouriez-Jones T, Crockford T, et al. Spontaneous class switching and B cell hyperactivity increase autoimmunity against intracellular self antigen in Lyn-deficient mice. Eur J Immunol. 2006;36:2920-2927.
103. Carnahan J, Wang P, Kendall R, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: Characterization of in vitro properties. Clin Cancer Res. 2003;9:3982S-3990S.
104. O'Reilly MK, Tian H, Paulson JC. CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells. J Immunol. 2011;186:1554-1563.
105. Weiner GJ. Rituximab:mechanism of action. Semin Hematol. 2010;47:115-123.
106. Conti F, Perricone C, Ceccarelli F, Valesini G. Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: Two sides of the same coin. Autoimmun Rev. 2010;9:716-720.
107. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: A randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;69:1629-1635.
108. Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2009;60:2156-2168.
109. Ding C, Foote S, Jones G. B-cell-targeted therapy for systemic lupus erythematosus: An update. Bio-Drugs. 2008;22:239-249.
110. Mariette X, Gottenberg JE, Ravaud P, Combe B. Registries in rheumatoid arthritis and autoimmune diseases: Data fromthe French registries. Rheumatology (Oxford). 2011;50:222-229.
111. Tony HP, Burmester G, Schulze-Koops H, et al. Safety and clinical outcomes of rituximab therapy in patientswith different autoimmune diseases: Experience froma national registry (GRAID). Arthritis ResTher. 2011;13:R75.
112. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab (LUNAR) study. Arthritis Rheum. 2012;64:1215-1226.
113. Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006;8:R74.
114. Jacobi AM, Goldenberg DM, Hiepe F, et al. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis. 2008;67:450-457.
115. Carnahan J, Stein R, Qu Z, et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a differentmode of action from rituximab.Mol Immunol. 2007;44:1331-1341.
116. Sieger N, Reiter K, Mei HE, et al. Epratuzumab inhibits upstream B cell receptor (BCR) signaling andmodulates Ca2+ flux upon activation. Presented at ACR 2011: Poster 1742.
117. Kalunian K, Wallace DJ, Petri M, et al. BILAG-measured improvement in moderately and severely affected body systems in patientswith systemic lupus erythematosus (SLE) by epratuzumab: Results from EMBLEM, a phase IIb study. Presented at EULAR 2010, Rome, Italy, 16-19 June 2010.
118. Wallace DJ, Kalunian K, Petri M, et al. Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): Results from EMBLEM, a phase IIb study. Presented atWorld Lupus Congress 2010.
119. Wallace DJ, Strand V, FurieR, et al. Evaluation of treatment success in systemic lupus erythematosus clinical trials: Development of the British Isles Lupus Assessment Group-based Composite Lupus Assessment Endpoint. Presented at ACR 2011: Poster 2265.
120. Goldenberg DM. Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev AnticancerTher. 2006;6:1341-1353.
121. Steinfeld SD, Tant L,BurmesterGR, et al. Epratuzumab (humanised anti-CD22 antibody) inprimary Sjogren's syndrome: An open-label phase I/II study. Arthritis ResTher. 2006;8:R129.